Positive Airway Pressure in a Patient with Heart Failure
A 61-year-old man with HFrEF (LVEF 30%, NYHA class II) and atrial fibrillation (on apixaban and metoprolol) is referred for sleepiness. He has a BMI of 34, neck circumference 17.5 inches, and reports loud snoring and witnessed apneas. He has paroxysmal nocturnal dyspnea and 2-pillow orthopnea. He is on guideline-directed medical therapy. A home sleep apnea test shows an AHI of 28 with a central apnea index of 2 and oxygen desaturation index of 22. The sleep physician is considering PAP therapy and asks whether ASV should be used because of his heart failure.
1. How would you interpret the home sleep apnea test in this patient, and what are its limitations given his comorbidities?
Read the worked answer
The HSAT shows moderate-severe OSA (AHI 28) with a low central apnea index (2) and significant desaturation (ODI 22). In a patient with HFrEF and AF, HSAT has important limitations:
- Under-detection of central events: HSAT devices that infer events from airflow and effort may misclassify or miss central sleep apnea, especially Cheyne-Stokes respiration, which is common in HFrEF. A central apnea index of 2 on HSAT is not reliable.
- No EEG/arousal data: HSAT cannot score hypopneas by arousal, so the AHI may be underestimated; it also cannot assess sleep architecture or PLMs.
- Nocturnal hypoxemia: ODI 22 is significant; in HF, this may reflect both OSA and central events or nocturnal hypoventilation.
- Positional and REM effects: HSAT may not capture REM-related events.
Given his HFrEF, paroxysmal nocturnal dyspnea, and orthopnea, in-lab polysomnography with the ability to score central events and, if needed, titration with CPAP/BPAP and assessment for Cheyne-Stokes is preferable before committing to a device strategy. HSAT is acceptable for uncomplicated OSA but not ideal here.
2. What is the evidence-based role of ASV in HFrEF, and what device strategy would you choose for this patient?
Read the worked answer
ASV in HFrEF: The SERVE-HF trial showed increased all-cause and cardiovascular mortality with ASV in patients with symptomatic HFrEF (LVEF ≤45%) and predominantly central sleep apnea. ASV is therefore contraindicated in patients with symptomatic HFrEF and LVEF ≤45% who have predominantly central sleep apnea. It is not appropriate here regardless of the central apnea index.
Device strategy for this patient:
- He has predominantly obstructive disease (AHI 28, low CAI on HSAT), so CPAP is the appropriate first-line therapy. Titrate in-lab to confirm control of obstructive events and to monitor for treatment-emergent central sleep apnea.
- If central sleep apnea emerges or predominates on titration, do not use ASV given LVEF 30%. Options include optimizing heart failure therapy, considering CPAP if obstructive events persist, and referral to advanced HF/cardiology for discussion of other strategies (e.g., phrenic nerve stimulation is not standard for HFrEF; acetazolamide or theophylline are not routine).
- BPAP with backup rate is not a substitute for ASV in this context and should be used cautiously.
Additional points:
- Optimize GDMT; treat AF per cardiology.
- Address sleepiness and confirm adherence; CPAP may improve AF burden and symptoms.
- Reassess LVEF and symptoms; if LVEF improves above 45%, the ASV contraindication may no longer apply, but this is a cardiology/ sleep medicine decision.
- Emphasize that the goal is to treat OSA without causing harm; ASV is not a benign 'upgrade'.